FDA Digital Health Advisory Committee

The U.S. Food and Drug Administration (FDA) recently created a Digital Health Advisory Committee to provide relevant expertise and perspective to improve the FDA’s understanding of the benefits, risks, and clinical outcomes associated with use of Digital Health Technologies (DHTs),” as well as identify “risks, barriers, or unintended consequences that could result from proposed or established FDA policy or regulation for topics related to DHTs.”  The Committee will consist of a core of nine voting members, including the Chair, selected by the FDA Commissioner or designee from among authorities knowledgeable in the fields of digital health.  Temporary members will also be selected for particular meetings, depending upon meeting topics.  “The FDA is looking to solicit views from technical and scientific subject matter experts from diverse disciplines and backgrounds,” and Committee nominations are due December 11, 2023.  For additional information, see the FDA Digital Health Advisory Committee and Advisory Committees pages.